CA2057524A1 - Dihydro-isoquinoline derivatives - Google Patents

Dihydro-isoquinoline derivatives

Info

Publication number
CA2057524A1
CA2057524A1 CA002057524A CA2057524A CA2057524A1 CA 2057524 A1 CA2057524 A1 CA 2057524A1 CA 002057524 A CA002057524 A CA 002057524A CA 2057524 A CA2057524 A CA 2057524A CA 2057524 A1 CA2057524 A1 CA 2057524A1
Authority
CA
Canada
Prior art keywords
compound
ester
formula
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002057524A
Other languages
English (en)
French (fr)
Inventor
Reto Naef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2057524A1 publication Critical patent/CA2057524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CA002057524A 1990-12-13 1991-12-12 Dihydro-isoquinoline derivatives Abandoned CA2057524A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027055A GB9027055D0 (en) 1990-12-13 1990-12-13 Organic compounds
GB9027055 1990-12-13

Publications (1)

Publication Number Publication Date
CA2057524A1 true CA2057524A1 (en) 1992-06-14

Family

ID=10686945

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002057524A Abandoned CA2057524A1 (en) 1990-12-13 1991-12-12 Dihydro-isoquinoline derivatives

Country Status (25)

Country Link
US (1) US5177085A (enExample)
EP (1) EP0490823B1 (enExample)
JP (1) JPH0764820B2 (enExample)
KR (1) KR920012040A (enExample)
AT (1) ATE145201T1 (enExample)
AU (1) AU643575B2 (enExample)
CA (1) CA2057524A1 (enExample)
CZ (1) CZ281669B6 (enExample)
DE (1) DE69123124T2 (enExample)
DK (1) DK0490823T3 (enExample)
ES (1) ES2093694T3 (enExample)
FI (1) FI915844L (enExample)
GB (1) GB9027055D0 (enExample)
GR (1) GR3022034T3 (enExample)
HU (1) HUT61729A (enExample)
IE (1) IE914325A1 (enExample)
IL (1) IL100328A (enExample)
MX (1) MX9102502A (enExample)
MY (1) MY129941A (enExample)
NZ (1) NZ240936A (enExample)
PL (1) PL168329B1 (enExample)
PT (1) PT99775B (enExample)
RU (1) RU2060992C1 (enExample)
TW (1) TW201736B (enExample)
ZA (1) ZA919858B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
RU2161967C2 (ru) * 1994-08-18 2001-01-20 Дзе Проктер Энд Гэмбл Компани Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
KR100358922B1 (ko) * 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
AU4527996A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6268373B1 (en) * 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
GB9523267D0 (en) * 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998017636A1 (en) * 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
ID19155A (id) * 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
WO1998038168A1 (en) * 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DE69822162T2 (de) * 1997-07-25 2005-01-27 Altana Pharma Ag Neue tetrazolderivate
JP2001518468A (ja) * 1997-09-30 2001-10-16 モレキュラー デザインズ インターナショナル，インコーポレイテッド β３アドレナリン受容体拮抗薬、拮抗薬合成物およびこれらの応用方法
IT1296985B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EP1671651B1 (en) 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1270577B1 (en) * 2000-03-23 2006-12-06 Takeda Pharmaceutical Company Limited Furoisoquinoline derivatives, process for producing the same and use thereof
AU2954102A (en) 2000-11-14 2002-05-27 Byk Gulden Lomberg Chem Fab (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
WO2002040449A1 (en) * 2000-11-14 2002-05-23 Altana Pharma Ag Dihydroisoquinolines as novel phosphodiesterase inhibitors
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
CA2449118A1 (en) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE435202T1 (de) 2002-01-11 2009-07-15 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
RS20050117A (sr) * 2002-08-17 2007-06-04 Altana Pharma Ag., Novi benzonaftiridini
WO2004018431A2 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
EP1536798B1 (en) 2002-08-29 2007-02-07 ALTANA Pharma AG 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
CA2495827C (en) 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
RU2355686C2 (ru) * 2003-10-16 2009-05-20 Ф.Хоффманн-Ля Рош Аг Ингибиторы глутаминфруктозо-6-фосфатамидотрансферазы
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
RU2332212C2 (ru) 2004-02-24 2008-08-27 Санкио Компани, Лимитед Аминоспирт
PT1723135E (pt) 2004-03-03 2013-08-29 Takeda Gmbh Novas hidroxi-6-heteroarilfenantridinas e sua utilização como inibidores de pde4
RU2281100C1 (ru) * 2005-01-11 2006-08-10 Общество с ограниченной ответственностью "Синтез-2000" Спазмолитическое средство
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3033082B1 (en) 2013-08-16 2021-06-16 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400425A (en) * 1971-09-22 1975-07-16 Rolland Sa A Substituted 3-hydroxymethyl-isoquinolines and derivatives
HU196758B (en) * 1986-05-21 1989-01-30 Gyogyszerkutato Intezet Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
PH25651A (en) * 1986-05-21 1991-08-21 Duphar Int Res New di, tetrahydroisoquinoline derivatives
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds

Also Published As

Publication number Publication date
NZ240936A (en) 1993-09-27
ES2093694T3 (es) 1997-01-01
RU2060992C1 (ru) 1996-05-27
PT99775B (pt) 1999-05-31
US5177085A (en) 1993-01-05
FI915844A7 (fi) 1992-06-14
IE914325A1 (en) 1992-06-17
TW201736B (enExample) 1993-03-11
KR920012040A (ko) 1992-07-25
PT99775A (pt) 1992-11-30
MY129941A (en) 2007-05-31
ZA919858B (en) 1993-06-14
MX9102502A (es) 1992-06-01
AU643575B2 (en) 1993-11-18
DK0490823T3 (enExample) 1997-02-17
PL292738A1 (en) 1992-12-14
HU913760D0 (en) 1992-02-28
FI915844A0 (fi) 1991-12-11
EP0490823A1 (en) 1992-06-17
IL100328A (en) 1995-12-08
HUT61729A (en) 1993-03-01
PL168329B1 (pl) 1996-02-29
CS375791A3 (en) 1992-06-17
GB9027055D0 (en) 1991-02-06
AU8898591A (en) 1992-06-18
IL100328A0 (en) 1992-09-06
EP0490823B1 (en) 1996-11-13
JPH0764820B2 (ja) 1995-07-12
DE69123124T2 (de) 1997-05-15
DE69123124D1 (de) 1996-12-19
CZ281669B6 (cs) 1996-12-11
ATE145201T1 (de) 1996-11-15
FI915844L (fi) 1992-06-14
JPH04275276A (ja) 1992-09-30
GR3022034T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
EP0490823B1 (en) Dihydro-isoquinoline derivates
CA1332944C (en) Isoquinoline derivatives, their preparation and their use
US5747506A (en) Isoquinoline compounds, compositions containing them and their pharmaceutical uses
EP0873338A1 (en) Quinoline derivatives as type iv phosphodiesterase inhibitors
US4822800A (en) Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US5137914A (en) Sulfonylamino substituted bicyclo [2.2.1]heptane hydroxamic acid derivatives useful as pharmaceuticals
PT828733E (pt) Benzopiranos e composicoes farmaceuticas que os contem
JPH0676373B2 (ja) グアニジノ安息香酸エステル誘導体
Shimoji et al. Synthesis and biological action of aminotetrahydroisoquinocarbazoles and related compounds: a new class of compounds with antiarrhythmic activity
US5059607A (en) Imidazolyl benzisoquinolines useful as 5-ht3 receptor antagonists
WO1994012493A1 (en) 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
EP0435235A1 (en) Isoquinoline derivatives and salts thereof as protease inhibitors.
NO178430B (no) Nye dihydroisokinolinderivater og deres anvendelse som terapeutikum
RO109541B1 (ro) Derivați de dihidro-izochinolină, procedee de obținere și compoziții farmaceutice
KR20020082300A (ko) 신규 테트라하이드로이소퀴놀린계 거울상 이성질체 화합물및 그의 약학적으로 허용되는 염, 그 제조방법 및 이를포함하는 약학적 조성물
JPH07118247A (ja) チアゾール酢酸誘導体
EP0623129A1 (en) 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals

Legal Events

Date Code Title Description
FZDE Discontinued